CFTR and cystic fibrosis: Treatment of primary cells from individuals with CF restored forskolin-activated Cl− secretion and the post-translational modification of ΔF508-CFTR (Rubenstein et al., 1997), and in vivo, orally administered 4PBA improved the nasal potential difference response in CF patients with minimal side-effects (Zeitlin et al., 2002).